Walmart sells virtual care business to Fabric

Walmart’s virtual patient care business, MeMD, has been acquired by Fabric, a healthcare technology company. The purchase was announced on Friday. 

MeMD offers virtual, on-demand healthcare services—including urgent and primary care along with behavioral health—to 5 million patients and serves more than 30,000 employer health plans. It was founded in 2010 and acquired by Walmart in 2021. 

The buyout coincides with Walmart shuttering its health clinics and telehealth services. The dollar amount of the sale was not revealed. However, MeMD has previously partnered with Fabric, which provides technology to make virtual patient intake and care management possible on the platform.

"The MeMD team built a leading virtual care offering, and we are excited to welcome them to Fabric," Aniq Rahman, founder and CEO of Fabric said in a statement. "This acquisition aligns with our strategic vision to transform healthcare delivery through innovative technology and exceptional patient care. The combination of our teams, technology and clinicians strategically positions Fabric to quickly expand across payers, employers and provider organizations."

Fabric said it will be a smooth transition for MeMD patients, adding that care will not be disrupted. Additionally, members of Sam’s Club who currently have access will still be served after the acquisition is finalized.

Chad Van Alstin Health Imaging Health Exec

Chad is an award-winning writer and editor with over 15 years of experience working in media. He has a decade-long professional background in healthcare, working as a writer and in public relations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.